Insmed (INSM) Competitors $97.94 +7.01 (+7.70%) Closing price 03:59 PM EasternExtended Trading$95.96 -1.98 (-2.02%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock INSM vs. TAK, ALNY, ONC, TEVA, RPRX, UTHR, ITCI, GMAB, SMMT, and RDYShould you be buying Insmed stock or one of its competitors? The main competitors of Insmed include Takeda Pharmaceutical (TAK), Alnylam Pharmaceuticals (ALNY), Beigene (ONC), Teva Pharmaceutical Industries (TEVA), Royalty Pharma (RPRX), United Therapeutics (UTHR), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Summit Therapeutics (SMMT), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical preparations" industry. Insmed vs. Takeda Pharmaceutical Alnylam Pharmaceuticals Beigene Teva Pharmaceutical Industries Royalty Pharma United Therapeutics Intra-Cellular Therapies Genmab A/S Summit Therapeutics Dr. Reddy's Laboratories Insmed (NASDAQ:INSM) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, community ranking, dividends, analyst recommendations, profitability, earnings, valuation and risk. Which has higher valuation and earnings, INSM or TAK? Takeda Pharmaceutical has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInsmed$381.03M46.82-$749.57M-$5.95-16.46Takeda Pharmaceutical$4.58T0.01$994.06M$0.2269.02 Is INSM or TAK more profitable? Takeda Pharmaceutical has a net margin of 4.53% compared to Insmed's net margin of -251.24%. Takeda Pharmaceutical's return on equity of 9.39% beat Insmed's return on equity.Company Net Margins Return on Equity Return on Assets Insmed-251.24% -4,773.73% -54.58% Takeda Pharmaceutical 4.53%9.39%4.53% Do institutionals & insiders hold more shares of INSM or TAK? 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 3.0% of Insmed shares are owned by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more volatility & risk, INSM or TAK? Insmed has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 0.23, suggesting that its stock price is 77% less volatile than the S&P 500. Does the media refer more to INSM or TAK? In the previous week, Insmed had 61 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 64 mentions for Insmed and 3 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 1.04 beat Insmed's score of 0.58 indicating that Takeda Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 29 Very Positive mention(s) 8 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Takeda Pharmaceutical 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in INSM or TAK? Insmed received 469 more outperform votes than Takeda Pharmaceutical when rated by MarketBeat users. Likewise, 67.38% of users gave Insmed an outperform vote while only 57.06% of users gave Takeda Pharmaceutical an outperform vote. CompanyUnderperformOutperformInsmedOutperform Votes57067.38% Underperform Votes27632.62% Takeda PharmaceuticalOutperform Votes10157.06% Underperform Votes7642.94% Do analysts prefer INSM or TAK? Insmed presently has a consensus price target of $104.19, indicating a potential upside of 6.38%. Given Insmed's higher possible upside, equities analysts plainly believe Insmed is more favorable than Takeda Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Insmed 0 Sell rating(s) 0 Hold rating(s) 18 Buy rating(s) 0 Strong Buy rating(s) 3.00Takeda Pharmaceutical 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryTakeda Pharmaceutical beats Insmed on 9 of the 17 factors compared between the two stocks. Get Insmed News Delivered to You Automatically Sign up to receive the latest news and ratings for INSM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INSM vs. The Competition Export to ExcelMetricInsmedPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.84B$6.84B$5.57B$8.60BDividend YieldN/A2.49%5.27%4.19%P/E Ratio-17.528.7927.2720.06Price / Sales46.82255.05409.23156.87Price / CashN/A65.8538.2534.64Price / Book-42.216.557.064.70Net Income-$749.57M$143.71M$3.23B$247.80M7 Day Performance32.90%3.76%2.69%2.17%1 Month Performance50.49%13.97%12.06%9.41%1 Year Performance58.29%4.76%31.40%14.73% Insmed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INSMInsmed3.2343 of 5 stars$97.94+7.7%$104.81+7.0%+51.8%$17.84B$381.03M-17.52373Trending NewsAnalyst ForecastAnalyst RevisionHigh Trading VolumeTAKTakeda Pharmaceutical2.0387 of 5 stars$15.07+0.2%N/A+12.9%$47.90B$4.58T37.6447,300Positive NewsALNYAlnylam Pharmaceuticals3.8468 of 5 stars$305.84+0.4%$319.17+4.4%+97.1%$39.88B$2.35B-140.942,000Positive NewsONCBeigene1.2569 of 5 stars$245.36-0.1%$319.00+30.0%N/A$24.35B$4.18B-29.789,000Trending NewsInsider TradeGap UpTEVATeva Pharmaceutical Industries4.0837 of 5 stars$17.26+2.8%$24.50+42.0%+4.5%$19.54B$16.62B-11.8936,800RPRXRoyalty Pharma4.7192 of 5 stars$33.24+1.1%$42.50+27.9%+22.6%$18.66B$2.26B22.8980Positive NewsUTHRUnited Therapeutics4.9701 of 5 stars$325.29+2.0%$393.00+20.8%+2.2%$14.67B$2.99B14.29980Trending NewsInsider TradeAnalyst RevisionITCIIntra-Cellular Therapies0.8211 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S3.7494 of 5 stars$21.78+3.9%$39.17+79.9%-18.2%$13.96B$3.12B12.511,660Positive NewsGap UpSMMTSummit Therapeutics2.9218 of 5 stars$17.77-2.5%$37.40+110.4%+176.7%$13.20B$700,000.00-63.47110Trending NewsAnalyst ForecastAnalyst RevisionGap DownHigh Trading VolumeRDYDr. Reddy's Laboratories1.1802 of 5 stars$14.73+0.0%$17.00+15.4%+9.5%$12.28B$325.54B23.4324,800 Related Companies and Tools Related Companies Takeda Pharmaceutical Competitors Alnylam Pharmaceuticals Competitors Beigene Competitors Teva Pharmaceutical Industries Competitors Royalty Pharma Competitors United Therapeutics Competitors Intra-Cellular Therapies Competitors Genmab A/S Competitors Summit Therapeutics Competitors Dr. Reddy's Laboratories Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INSM) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insmed Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Insmed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy INSM Stock Free INSM Stock Alerts